Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Meisner

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II TrialThomas E Mürdter, Werner Schroth, Matthew P Goetz, et al.
Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.
The Lancet. Oncology|May 15, 2012
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialWolfgang Wick, Michael Platten, Christoph Meisner, et al.
Annals of Neurology|February 9, 2002
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphomaUlrich Herrlinger, Martin Schabet, Wolfram Brugger, et al.
Neurology|September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationWolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Cancers|March 11, 2023
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology GroupChristoph Thomssen, Martina Vetter, Eva J Kantelhardt, et al.
Cancer Medicine|September 29, 2020
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genesTobias Kessler, Anne Berberich, Ahmed Sadik, et al.
Onkologie|September 13, 2007
Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre studySven Bornhak, Else Heidemann, Hans-Joachim Herschlein, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II TrialThomas E Mürdter, Werner Schroth, Matthew P Goetz, et al.
Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.
The Lancet. Oncology|May 15, 2012
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialWolfgang Wick, Michael Platten, Christoph Meisner, et al.
Annals of Neurology|February 9, 2002
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphomaUlrich Herrlinger, Martin Schabet, Wolfram Brugger, et al.
Neurology|September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationWolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Cancers|March 11, 2023
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology GroupChristoph Thomssen, Martina Vetter, Eva J Kantelhardt, et al.
Cancer Medicine|September 29, 2020
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genesTobias Kessler, Anne Berberich, Ahmed Sadik, et al.
Onkologie|September 13, 2007
Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre studySven Bornhak, Else Heidemann, Hans-Joachim Herschlein, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Pageof 10